Mandate

Vinge has advised Cellink in a directed new issue of shares of MSEK 100

Vinge has advised Cellink AB (publ) in connection with a directed new issue of shares to Swedish and internationally well-reputed investors such as the Swedish Fourth AP Fund (AP4), Carl Bennet AB, Claes Dinkelspiel and Handelsbanken Fonder.

The subscription price in the amount of SEK 132.50 has been determined through a so called accelerate bookbuilding procedure. As a result of the new issue, Cellink will receive approximately MSEK 100. The proceeds generated by the new issue of shares will be used, among other things, in order to perform acquisitions in accordance with Cellink’s growth strategy, continued global expansion and future development of its product portfolio. Carnegie Investment

Bank has acted as financial advisor and sole bookrunner.

Vinge’s team consisted of partner Anders Strid together with, among others, Wibeke Sorling and company assistant Camilla Andersson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025